Targeting the HIF2–VEGF axis in renal cell carcinoma
The DOI matches its Crossref record; 177 of the 179 references it cites were found in a registry or an index.
Abstract
Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as VEGF, for the treatment of cancers caused by VHL inactivation, such as clear-cell renal cell carcinoma (ccRCC). Multiple VEGF inhibitors are now approved for the treatment of ccRCC, and a HIF2α inhibitor has advanced to phase 3 development for this disease. These inhibitors are now also increasingly combined with immune-checkpoint blockers. In this Perspective, we describe the understanding of the mechanisms of oxygen sensing and hypoxia signaling that resulted in the development of HIF2α-targeted therapies for patients with VHL-associated tumors. We also present future directions for extending the use of these therapies to other cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Genetic and functional studies have supported a pro-tumorigenic role of HIF-2α, and a tumor suppressor role for HIF-1α in ccRCC, which has prompted the development of HIF-2α specific inhibitors [17].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [17]
In the citing paper
“HIF‐1‐induced proteins include VEGF, which promotes vascular permeability, and basic fibroblast growth factor (bFGF), which promotes endothelial cell growth.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [72]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Self-citationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citation
Research works printed but not linked: 3
- Choueiri, T. et al. Randomised phase 2 study of sapanisertib (TAK 228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma. Fourteenth European International Kidney Cancer Symposium (2019).
- Mohlin, S., von Stedingk, K., Pietras, A. & Påhlman, S. No reason to reconsider HIF-2 as an oncogene in neuroblastoma and other cancer forms. Proc. Natl Acad. Sci. USA 114, E10856–E10858 (2017). · DOI
- Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015). · DOI · Paper page
Cited by
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
Self-citationBelzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714
“Upper respiratory tract infection 11 (18) 4 (7) 7 (11) 0”
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
“The occurrence of pVHL tumor suppressor inactivation is a major event in ccRCC.(448) Hypoxia signaling in human health and diseases: implications and.”
BackgroundZhang, Y., Narayanan, S. P., Mannan, R., Raskind, G., Wang, X., Vats, P., Su, F., Hosseini, N., Cao, X., Kumar-Sinha, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103240118 · Cited by 377
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356
Self-citation
Metadata
- Authors
- Choueiri, T. K., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Choueiri, Toni K.
- Kaelin, William G.
- Venue
- Nature Medicine
- Published
- 2020-10-01
- Volume
- 26
- Issue
- 10
- Pages
- 1519-1530
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3089803871
- Semantic Scholar
- e1c917d496030f5e9200abccd47bac9a637136a7
- Cited by
- 477
- References
- 179
- Citations by year
- 2026: 60 · 2025: 68 · 2024: 83 · 2023: 93 · 2022: 100 · 2021: 72 · 2020: 1
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-08-28)
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-2α, vascular endothelial growth factor, clear cell renal cell carcinoma, VHL, oxygen sensing, hypoxia signaling, VEGF inhibitors, immune checkpoint inhibitors, combination therapy
- MeSH terms
- Tumor Hypoxia, Endothelial PAS Domain-Containing Protein 1, Antineoplastic Agents, Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Oxygen, Signal Transduction, Gene Expression Regulation, Neoplastic, Cell Respiration, Vascular Endothelial Growth Factor A, Basic Helix-Loop-Helix Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the HIF2–VEGF axis in renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41591-020-1093-z
- The paper
- Choueiri, T. K., & Kaelin, W. G. (2020). Targeting the HIF2–VEGF axis in renal cell carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-020-1093-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.